Lv7
5000 积分 2023-11-15 加入
Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer
2个月前
已完结
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
2个月前
已完结
Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT/IDEA pooled analysis of seven trials
2个月前
已完结
Colorectal cancer with BRAF V600E mutation: Trends in immune checkpoint inhibitor treatment
2个月前
已完结
SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAF V600E-mutant mCRC
2个月前
已完结
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer
2个月前
已完结
Activity and safety of atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE): a multicentre, single-arm, phase 2 trial
2个月前
已完结
Duration of Immunotherapy in dMMR/MSI-H Metastatic Colorectal Cancer Patients
3个月前
已完结
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
3个月前
已完结
Responsiveness to Cetuximab without Mutations inEGFR
3个月前
已完结
皖公网安备34019202002308
